Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
TV & Film
Technology
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/5e/b5/34/5eb534a8-ffe2-2455-ddff-eb0eadd77851/mza_8788355609034046974.jpg/600x600bb.jpg
At the Intersection of Science and Law
DLA Piper
14 episodes
9 months ago
In DLA Piper’s At the Intersection of Science and Law podcast, members of the firm’s Life Sciences team explore the connection between science and the law in areas that include AI and drug discovery, mRNA technology, and the regulatory implications of new drugs and devices.
Show more...
Life Sciences
Technology,
Science
RSS
All content for At the Intersection of Science and Law is the property of DLA Piper and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In DLA Piper’s At the Intersection of Science and Law podcast, members of the firm’s Life Sciences team explore the connection between science and the law in areas that include AI and drug discovery, mRNA technology, and the regulatory implications of new drugs and devices.
Show more...
Life Sciences
Technology,
Science
https://www.omnycontent.com/d/clips/f0ba31af-ed56-445e-8866-ab8b018b22a8/9b9b492d-5b9c-4858-b0af-ae12010719e0/4c6c5a71-31bc-4876-8342-ae1201073377/image.jpg?t=1641225498&size=Large
The crossroad of science and law
At the Intersection of Science and Law
26 minutes
3 years ago
The crossroad of science and law
In this episode, DLA Piper’s Lucas Przymusinski and Raymond Williams are joined by Michael King, Vice President and Associate General Counsel at Jazz Pharmaceuticals, to discuss the benefits of medical and science backgrounds when litigating matters...
At the Intersection of Science and Law
In DLA Piper’s At the Intersection of Science and Law podcast, members of the firm’s Life Sciences team explore the connection between science and the law in areas that include AI and drug discovery, mRNA technology, and the regulatory implications of new drugs and devices.